PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

The following article was originally published by Perkin Elmer:

WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 21, 2020– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for both decentralized sample collection and high-throughput testing. The product is being marketed as a CE-IVD test, and the Company plans to apply for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA).

Read Full Article >

Categories
Archives
READY TO LEARN MORE?

Connected Health Starts Here